Stock Price Quote

DR. REDDY'S LABORATORIES LTD.

NSE : DRREDDYBSE : 500124ISIN CODE : INE089A01031Industry : Pharmaceuticals & DrugsHouse : Dr. Reddy's
BSE1234.555.3 (+0.43 %)
PREV CLOSE ( ) 1229.25
OPEN PRICE ( ) 1241.75
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 33002
TODAY'S LOW / HIGH ( )1227.65 1242.00
52 WK LOW / HIGH ( )1025.9 1404.6
NSE1234.905.3 (+0.43 %)
PREV CLOSE( ) 1229.60
OPEN PRICE ( ) 1235.80
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 1234.90 (73)
VOLUME 1426984
TODAY'S LOW / HIGH( ) 1227.30 1242.40
52 WK LOW / HIGH ( )1020 1405.9
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 24-02 1984
Management Info
K Satish Reddy - Chairman GV Prasad - Managing Director
Registered Office

Address 8-2-337,Road No. 3,Banjara Hills,
Hyderabad,
Telangana-500034

Phone 040 - 4900 2900

Email mail@drreddys.com / shares@drreddys.com

Website www.drreddys.com

Registrars Details
Bigshare Services Pvt Ltd
306, Right Wing, Amrutha Ville, Opp. Yasodha Hospital,Raj Bhavan Road,Somajiguda,Hyderabad
Listing : BSE, NSE, New York

NEWS

10Nov Clarification sought from Dr Reddys L
The Exchange has sought clarification from Dr Reddys Laboratories Ltd, w..
24Oct Dr Reddy's Laboratories reports 7% ris
Dr Reddy's Laboratories has reported result for second quarter ended Sep..
23Oct Dr. Reddy's gets EIR for formulations
Dr. Reddy's Laboratories has received the Establishment Inspection Repor..
16Oct Dr Reddys Laboratories informs about d
Dr Reddys Laboratories has informed that the exchange has received the d..
13Oct Dr. Reddy's Lab’s arm recalls affected
Dr. Reddy's Laboratories’ American subsidiary is recalling 571 vials of..

Financials

in Millions
QTR Sep 25 ANNUAL 25
Net Profit387353494
Gross Profit 5163 72359
Operating Profit 844583852
Net Sales 46186231154

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Sanofi Cons. Health (BSE)
peergroup  4986.40 (7.07%)
M.Cap ( in Cr)11483.99
Kwality Pharma (BSE)
peergroup  971.40 (10.24%)
M.Cap ( in Cr)1007.94
Divi's Lab (BSE)
peergroup  6589.65 (1.08%)
M.Cap ( in Cr)174934.50
Strides Pharma Scien (BSE)
peergroup  973.80 (5.44%)
M.Cap ( in Cr)8975.78
Emcure Pharma (BSE)
peergroup  1380.60 (3.10%)
M.Cap ( in Cr)26171.32

Shareholding Pattern

NON-INSTITUTION 9.86%
PROMOTERS 26.64%
MUTUAL FUNDS/UTI 13.31%
FI/BANKS/INSURANCE 11.93%
GOVERNMENT 0%
FII 0%

About Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Ltd. was incorporated in the year 1984. Its today's share price is 1234.55. Its current market capitalisation stands at Rs 103038.16 Cr. In the latest quarter, company has reported Gross Sales of Rs. 231154 Cr and Total Income of Rs.241188 Cr. The company's management includes Alpna Hansraj Seth, Sanjiv Mehta, Claudio Albrecht, Arun Kumar, Penny Wan, K P Krishnan, Shikha Sharma, Leo Puri, GV Prasad, K Satish Reddy, K Randhir Singh.

It is listed on the BSE with a BSE Code of 500124 , NSE with an NSE Symbol of DRREDDY and ISIN of INE089A01031. It's Registered office is at 8-2-337,Road No. 3,Banjara HillsHyderabad-500034, Telangana. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are A Rama Chandra Rao & Co, Bharat S Raut & Co, BSR & Co, BSR & Co LLP, SR Batliboi & Associates LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.